Listed

Chemed Corp: Form 10-Q for the period ended Sep 30, 2021

Filed with the SEC on Nov 1, 2021 and accepted by EDGAR at Nov 1, 2021, 09:48 ET.

Share

Management's discussion and analysis

As filed, 54,820 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Executive Summary

We operate through our two wholly-owned subsidiaries, VITAS Healthcare Corporation and Roto-Rooter Group, Inc. VITAS focuses on hospice care that helps make terminally ill patients’ final days as comfortable as possible. Through its teams of doctors, nurses, home health aides, social workers, clergy and volunteers, VITAS provides direct medical services to patients, as well as spiritual and emotional counseling to both patients and their families. Roto-Rooter’s services are focused on providing plumbing, drain cleaning, water restoration and other related services to both residential and commercial customers. Through its network of company-owned branches, independent contractors and franchisees, Roto-Rooter offers plumbing and drain cleaning service to over 90% of the U.S. population.

The following is a summary of the key operating results (in thousands except per share amounts):

Three months ended September 30, 2021 2020 Nine months ended September 30, 2021 2020
Service revenues and sales $538,667 $528,297 $1,598,283 $1,546,294
Net income $72,003 $67,722 $193,925 $205,714
Diluted EPS $4.55 $4.14 $12.06 $12.53
Adjusted net income $80,084 $79,556 $226,554 $212,494
Adjusted diluted EPS $5.06 $4.86 $14.09 $12.94
Adjusted EBITDA $119,373 $117,805 $338,840 $319,576
Adjusted EBITDA as a % of revenue 22.2% 22.3% 21.2% 20.7%

Adjusted net income, adjusted diluted EPS, earnings before interest, taxes and depreciation and amortization (“EBITDA”), Adjusted EBITDA and Adjusted EBITDA as a percent of revenue are not measures derived in accordance with US GAAP. We provide non-GAAP measures to help readers evaluate our operating results and to compare our operating performance with that of similar companies that have different capital structures. Our non-GAAP measures should not be considered in isolation or as a substitute for comparable measures presented in accordance with GAAP. A reconciliation of our non-GAAP measures is presented on pages 36-38.

For the three months ended September 30, 2021, the increase in consolidated service revenues and sales was driven by a 15.7% increase at Roto-Rooter offset by a 5.8% decrease at VITAS. The increase in service revenues at Roto-Rooter was driven by an increase in all major service lines. Roto-Rooter’s third quarter 2020 revenue was significantly impacted by shut-downs resulting from the COVID pandemic. The decrease in service revenues at VITAS is comprised primarily of a 5.3% decrease in days-of-care offset by a geographically weighted average Medicare reimbursement rate increase (including the suspension of sequestration on May 1, 2020) of approximately 1.2%. Acuity mix shift had a net impact of reducing revenue approximately $3.0 million, or 0.9% in the quarter when compared to the prior year revenue and level-of-care mix. The combination of a Medicare cap revenue reduction and other contra revenue changes negatively impacted revenue growth by approximately 80 basis points. See page 39 for additional VITAS operating metrics.

For the nine months ended September 30, 2021, the increase in consolidated service revenues and sales was driven by a 20.1% increase at Roto-Rooter offset by a 5.7% decrease at VITAS. The increase in service revenues at Roto-Rooter was driven by an increase in all major service lines. Roto-Rooter’s first nine months 2020 revenue was significantly impacted by the COVID pandemic. The decrease in service revenues at VITAS is comprised primarily of a 6.2% decrease in days-of-care offset by a geographically weighted average Medicare reimbursement rate increase (including the suspension of sequestration on May 1, 2020) of approximately 1.9%. Acuity mix shift had a net impact of reducing revenue approximately $16.0 million, or 1.6% in the quarter when compared to the prior year revenue and level-of-care mix. The combination of a lower Medicare cap revenue reduction and other contra revenue changes offset a portion of the revenue decline by approximately 20 basis points. See page 39 for additional VITAS operating metrics.

The current COVID-19 pandemic did have a material impact on our business operations, results of operations, cash flow and financial position as of and for the three months and nine months ended September 30, 2021 and 2020, respectively. We are closely monitoring the impact of the pandemic on all aspects of our business including impacts to employees, customers, patients, suppliers and vendors. The Company’s two operating subsidiaries have been categorized as critical infrastructure businesses and are not currently materially limited by federal, state or local regulations that restrict movement or operating ability.

The length and severity of the pandemic, coupled with related governmental actions including relief acts and actions relating to our workforce at federal, state and local levels, and underlying economic disruption will determine the ultimate short-term and long-term impact to our business operations and financial results. We are unable to predict the myriad of possible issues that could arise or the ultimate effect to our businesses as a result of the unknown short, medium and long-term impacts that the pandemic will have on the United States economy and society as a whole.

Historically, Chemed earnings guidance has been developed using previous years’ key operating metrics which are then modeled and projected out for the calendar year. Critical within these projections is the understanding of traditional patterned correlations among key operating metrics. This modeling exercise also takes into consideration anticipated industry and macro-economic issues outside of management’s control but are somewhat predictable in terms of timing and impact on our business segments’ operating results.

The COVID-19 pandemic has made accurate modeling and providing meaningful earnings guidance exceptionally challenging. Since the start of the pandemic, Chemed has been able to successfully navigate within this rapidly changing environment and produce operating results that we believe provide us with the ability to issue earnings guidance for the 2021 calendar year. However, this guidance should be taken with the recognition the pandemic will continue to disrupt our healthcare system and general economy to such an extent that future rules, regulations and government mandates could materially impact the company’s ability to achieve this guidance.

Statistically, patients residing in senior housing are identified as hospice appropriate earlier into their terminal prognosis and have a much greater probability of having a length of stay in excess of 90 days. Hospice patients referred from hospitals, oncology practices and similar referral sources are generally more acute and have a significantly lower probability of lengths-of-stay exceeding 90 days. According to data released by the National Investment Center for Seniors Housing & Care, COVID-19 continues to adversely affect senior housing occupancy. This reduced occupancy in senior housing has had a corresponding reduction in VITAS nursing home admissions. Nursing home patients represented 15.6% of VITAS’ third-quarter 2021 patient census. This compares to nursing home patients averaging 18.2% of total census just prior to the pandemic.

Based upon the above discussion, VITAS 2021 revenue, prior to Medicare Cap, is estimated to decline approximately 5% when compared to the prior year. Average Daily Census in 2021 is estimated to decline approximately 5.5%. Full-year Adjusted EBITDA margin, prior to Medicare Cap, is estimated to be 18.8%. We are currently estimating $6.6 million for Medicare Cap billing limitations in calendar year 2021.

Roto-Rooter is forecasted to achieve full-year 2021 revenue growth of 17.3%. Roto-Rooter’s Adjusted EBITDA margin for 2021 is estimated to be between 28.5% to 29.0%.

Based upon the above, full-year 2021 adjusted earnings per diluted share, excluding non-cash expense for stock options, tax benefits from stock option exercises, costs related to litigation, and other discrete items, is estimated to be in the range of $19.00 to $19.20. This compares to initial 2021 adjusted earnings per diluted share guidance of $17.00 to $17.50. This revised 2021 guidance assumes an effective corporate tax rate on adjusted earnings of 25.1%. Chemed’s 2020 reported adjusted earnings per diluted share was $18.08.

We anticipate that our operating income and cash flows will be sufficient to operate our businesses and meet any commitments for the foreseeable future.

Financial Condition

Liquidity and Capital Resources

Material changes in the balance sheet accounts from December 31, 2020 to September 30, 2021 include the following:

An $8.7 million decrease in accounts receivable due to timing of receipts.

A $6.3 million increase in prepaid income taxes due to timing of payments.

A $6.1 million increase in prepaid expense due primarily to a $6.0 million increase in prepaid software at VITAS.

A $13.2 million increase in investment of deferred compensation plans due primarily to contributions and market valuation gains. These gains are offset by expense recognized in the deferred compensation liability.

A $7.5 million decrease in identifiable intangible assets due to amortization.

A $5.8 million increase in accounts payable due to timing of payments.

A $6.0 million increase in accrued compensation due to accrual of additional paid time off for VITAS front line workers and an increase in accrued bonus.

A $9.1 million decrease in accrued legal mainly as a result of the payments of two legal settlements.

A $345.1 million increase in treasury stock due mainly to stock repurchases.

Net cash provided by operating activities decreased $157.4 million from September 30, 2020 to September 30, 2021. The main drivers of the decrease are a decrease in net income of $11.8 million, the Unutilized CARES Act grant received in 2020 of $48.0 million, the deferral of payroll taxes during the second quarter of 2020 of $22.9 million and increases in cash outflows associated with accounts payable and current income taxes of $39.6 million. Significant changes in our accounts receivable balances are typically driven by the timing of payments received from the Federal government at our VITAS subsidiary. We typically receive a payment in excess of $40.0 million from the Federal government for hospice services every other Friday. The timing of a period end will have a significant impact on the accounts receivable at VITAS. These changes generally normalize over a two year period, as cash flow variations in one year are offset in the following year.

Management continually evaluates cash utilization alternatives, including share repurchase, debt repurchase, acquisitions and increased dividends to determine the most beneficial use of available capital resources.

On June 20, 2018, we signed the Fourth Amended and Restated Credit Agreement (“2018 Credit Agreement”). Terms of the 2018 Credit Agreement consist of a five year, $450 million revolving credit facility and a $150 million expansion feature, which may consist of term loans or additional revolving commitments. The revolving credit facility has a five year maturity with principal payments due at maturity. The interest rate at the inception of the agreement was LIBOR plus 100 basis points. The 2018 Credit Agreement has a floating interest rate that is generally LIBOR plus a tiered additional rate which varies based on our current leverage ratio. We have no debt outstanding under the 2018 Credit Agreement as of September 30, 2021.

We have issued $46.2 million in standby letters of credit as of September 30, 2021, mainly for insurance purposes. Issued letters of credit reduce our available credit under the revolving credit agreement. As of September 30, 2021, we have approximately $403.8 million of unused lines of credit available and eligible to be drawn down under our revolving credit facility. Management believes its liquidity and sources of capital are satisfactory for the Company’s needs in the foreseeable future.

Commitments and Contingencies

Collectively, the terms of our credit agreements require us to meet various financial covenants, to be tested quarterly. We are in compliance with all financial and other debt covenants as of September 30, 2021 and anticipate remaining in compliance throughout the foreseeable future.

We are subject to various lawsuits and claims in the normal course of our business. In addition, we periodically receive communications from governmental and regulatory agencies concerning compliance with Medicare and Medicaid billing requirements at our VITAS subsidiary. We establish reserves for specific, uninsured liabilities in connection with regulatory and legal action that we deem to be probable and estimable. We disclose the existence of regulatory and legal actions when we believe it is reasonably possible that a loss could occur in connection with the specific action. In most instances, we are unable to make a reasonable estimate of any reasonably possible liability due to the uncertainty of the outcome and stage of litigation. We record legal fees associated with legal and regulatory actions as the costs are incurred.

See Note 11 in the Notes to the Unaudited Consolidated Financial Statements in Item 1 above for a description of current material legal matters.

Results of Operations

Three months ended September 30, 2021 versus 2020 - Consolidated Results

Our service revenues and sales for the third quarter of 2021 increased 2.0% versus services and sales revenues for the third quarter of 2020. Of this increase, a $30.1 million increase was attributable to Roto-Rooter offset by a $19.7 million decrease attributable to VITAS. The following chart shows the components of revenue by operating segment (in thousands):

VITAS Three months ended September 30, 2021 2020
Routine homecare $268,137 $278,856
Continuous care 22,027 30,699
General inpatient 29,368 27,633
Other 3,225 2,910
Medicare cap adjustment (97) 4,072
Room and board - net (2,130) (3,289)
Implicit price concessions (3,119) (3,784)
Roto-Rooter
Drain cleaning - short term core 63,072 55,527
Plumbing - short term core 45,124 39,439
Subtotal 108,196 94,966
Excavation - short term core 52,607 47,688
Water restoration 39,786 32,137
Contractor operations 18,969 16,274
Outside franchisee fees 1,260 1,235
Other - short term core 254 435
Other 3,773 3,332
Implicit price concessions (3,589) (4,867)
Total $538,667 $528,297

Days of care at VITAS during the quarter ended September 30 were as follows:

Days of Care 2021 2020 Increase/(Decrease) Percent
Routine homecare 1,342,841 1,426,191 (5.8)
Nursing home 258,700 261,396 (1.0)
Respite 5,331 4,566 16.8
Subtotal routine homecare and respite 1,606,872 1,692,153 (5.0)
Continuous care 24,299 33,013 (26.4)
General inpatient 27,962 27,017 3.5
Total days of care 1,659,133 1,752,183 (5.3)

The decrease in service revenues at VITAS is comprised primarily of a 5.3% decrease in days-of-care offset by a geographically weighted average Medicare reimbursement rate increase (including the suspension of sequestration on May 1, 2020) of approximately 1.2%. Acuity mix shift had a net impact of reducing revenue approximately $3.0 million, or 0.9% in the quarter when compared to the prior year revenue and level-of-care mix. The combination of Medicare cap revenue reduction and other contra revenue changes negatively impacted revenue growth by approximately 80 basis points.

The increase in plumbing revenues for the third quarter of 2021 versus 2020 is attributable to a 1.0% increase in job count and to a 13.4% increase in price and service mix shift. The increase in excavation revenues for the third quarter of 2021 versus 2020 is attributable to a 14.2% increase in price and service mix shift and a 3.9% decrease in job count. Drain cleaning revenues for the third quarter of 2021 versus 2020 reflect a 11.2% increase in price and service mix shift and a 2.4% increase in job count. Water restoration revenue increased for the third quarter of 2021 versus 2020 due to a 11.0% increase in job count and a 12.8% increase in price and service mix shift.

The consolidated gross margin was 36.5% in the third quarter of 2021 as compared with 35.8% in the third quarter of 2020. On a segment basis, VITAS’ gross margin was 25.0% in the third quarter of 2021 as compared with 26.8%, in the third quarter of 2020. The decrease is primarily due to the payout of discretionary bonuses. The Roto-Rooter segment’s gross margin was 53.0% for the third quarter of 2021 as compared with 51.6% in the third quarter of 2020 primarily due to increased revenue and improved labor costs.

Selling, general and administrative expenses (“SG&A”) comprise (in thousands):

Three months ended September 30, 2021 2020
SG&A expenses before long-term incentive compensation and the impact of market value adjustments related to deferred compensation trusts $84,197 $79,287
Impact of market value adjustments related to assets held in deferred compensation trusts 3,078 7,256
Long-term incentive compensation 1,942 1,774
Total SG&A expenses $89,217 $88,317

SG&A expenses before long-term incentive compensation and the impact of market value adjustments related to deferred compensation trusts for the third quarter of 2021 were up 6.2% when compared to the third quarter of 2020. This increase was mainly a result of the increase in variable selling and general administrative expenses and increased bonus expense at Roto-Rooter caused by increased income.

Depreciation for the third quarter of 2021 increased 1.1% when compared to the third quarter of 2020.

Amortization for the third quarter of 2021 was flat when compared to the third quarter of 2020. Quarterly amortization of intangible assets is mainly driven by two Roto-Rooter franchise acquisitions completed in 2019. The total purchase price of these acquisitions was $138.0 million. As part of the purchase price allocation, approximately $59.2 million was determined to be the value of reacquired franchise rights which are being amortized over the remaining life of each franchise agreement. The average remaining life on the reacquired franchise agreements was approximately seven years. Quarterly amortization of reacquired franchise rights for these two acquisitions is approximately $2.0 million ($8.1 million annualized through 2026). This contrasts to quarterly franchise fees historically collected from these two franchisees of approximately $470,000 ($1.9 million annualized).

Other operating expenses comprise the following:

Three months ended September 30, 2021 2020
Loss on disposal of fixed assets $63 $307
CARES Act grant - 8,805
Litigation settlement - 3,095
Total other operating expenses $63 $12,207

Other income – net comprise (in thousands):

Three months ended September 30, 2021 2020
Market value adjustment on assets held in deferred compensation trusts $3,078 $7,256
Interest income 57 423
Other (1) (4)
Total other income - net $3,134 $7,675

Our effective tax rate reconciliation is as follows (in thousands):

Three months ended September 30, 2021 2020
Income tax provision calculated at the statutory federal rate $20,038 $17,137
Stock compensation tax benefits (1,199) (7,187)
State and local income taxes 3,153 3,028
Other--net 1,425 904
Income tax provision $23,417 $13,882
Effective tax rate 24.5% 17.0%

Net income for both periods included the following after-tax items/adjustments that (reduced) or increased after-tax earnings (in thousands):

VITAS Three months ended September 30, 2021 2020
Direct costs related to COVID-19 $(1,866) $(5,181)
CARES Act grant - (6,528)
COVID-19 Medicare cap - 1,679
Medicare cap sequestration adjustment - 635
Roto-Rooter
Amortization of reacquired franchise agreements (1,729) (1,728)
Direct costs related to COVID-19 (305) (971)
Litigation settlements - (2,275)
Corporate
Stock option expense (3,462) (2,970)
Long-term incentive compensation (1,752) (1,682)
Excess tax benefits on stock compensation 1,199 7,187
Other (166) -
Total $(8,081) $(11,834)

Three months ended September 30, 2021 versus 2020 - Segment Results

Net income/(loss) for the third quarter of 2021 versus the third quarter of 2020 by segment (in thousands):

Three months ended September 30, 2021 2020
VITAS 42,950 $45,737
Roto-Rooter 44,554 31,176
Corporate (15,501) (9,191)
$72,003 $67,722

VITAS’ after-tax earnings decreased primarily due to lower revenue in the third quarter of 2021 when compared to the third quarter of 2020. After-tax earnings as a percent of revenue at VITAS in the third quarter of 2021 was 13.5% as compared to 13.6% in the third quarter of 2020.

Roto-Rooter’s net income was impacted in 2021 compared to 2020 primarily by higher revenue and improved labor costs. After-tax earnings as a percent of revenue at Roto-Rooter in the third quarter of 2021 was 20.1%, as compared to 16.3% in the third quarter of 2020.

After-tax Corporate expenses for 2021 increased 68.7% when compared to 2020 due mainly to a $6.0 million decrease in the excess tax benefits on stock compensation.

Results of Operations

Nine months ended September 30, 2021 versus 2020 - Consolidated Results

Our service revenues and sales for the first nine months of 2021 increased 3.4% versus services and sales revenues for the first nine months of 2020. Of this increase, $109.3 million was attributable to Roto-Rooter offset by a $57.3 million decrease attributable to VITAS. The following chart shows the components of revenue by operating segment (in thousands):

VITAS Nine months ended September 30, 2021 2020
Routine homecare $796,817 $826,954
Continuous care 73,658 105,836
General inpatient 85,895 85,983
Other 9,241 8,175
Medicare cap adjustment (3,597) (4,178)
Room and board - net (7,451) (9,317)
Implicit price concessions (9,428) (10,976)
Roto-Rooter
Drain cleaning - short term core 187,477 159,003
Plumbing - short term core 131,045 108,255
Subtotal 318,522 267,258
Excavation - short term core 159,714 135,425
Water restoration 115,804 92,810
Contractor operations 56,754 47,695
Outside franchisee fees 3,842 3,635
Other - short term core 853 1,371
Other 11,601 9,836
Implicit price concessions (13,942) (14,213)
Total $1,598,283 $1,546,294

Days of care at VITAS during the nine months ended September 30 were as follows:

Days of Care 2021 2020 Increase/(Decrease) Percent
Routine homecare 4,008,215 4,192,681 (4.4)
Nursing home 735,906 844,232 (12.8)
Respite 15,509 15,416 0.6
Subtotal routine homecare and respite 4,759,630 5,052,329 (5.8)
Continuous care 79,385 110,200 (28.0)
General inpatient 82,129 84,907 (3.3)
Total days of care 4,921,144 5,247,436 (6.2)

The decrease in service revenues at VITAS is comprised primarily of a 6.2% decrease in days-of-care offset by a geographically weighted average Medicare reimbursement rate increase (including the suspension of sequestration on May 1, 2020) of approximately 1.9%. Acuity mix shift had a net impact of reducing revenue approximately $16.0 million, or 1.6% in the quarter when compared to the prior year revenue and level-of-care mix. The combination of a lower Medicare cap revenue reduction and other contra revenue changes offset a portion of the revenue decline by approximately 20 basis points.

The increase in plumbing revenues for the first nine months of 2021 versus 2020 is attributable to a 12.3% increase in job count and to an 8.8% increase in price and service mix shift. The increase in excavation revenues for the first nine months of 2021 versus 2020 is attributable to a 9.2% increase in job count and to an 8.7% increase in price and service mix shift. Drain cleaning revenues for the first nine months of 2021 versus 2020 reflect a 9.1% increase in price and service mix shift and an 8.8% increase in job count. Water restoration revenue increased for the first nine months of 2021 versus 2020 due to a 10.2% increase in job count and a 14.6% increase in price and service mix shift. The increase in job count for all service lines was driven by both residential and commercial customers.

The consolidated gross margin was 35.4% in the first nine months of 2021 as compared with 32.5% in the first nine months of 2020. On a segment basis, VITAS’ gross margin was 23.4% in the first nine months of 2021 as compared with 22.9%, in the first nine months of 2020. The increase is primarily due to improved labor costs. The Roto-Rooter segment’s gross margin was 52.7% for the first nine months of 2021 as compared with 50.3% in the first nine months of 2020 primarily due to increased revenue and improved labor costs.

Selling, general and administrative expenses (“SG&A”) comprise (in thousands):

Nine months ended September 30, 2021 2020
SG&A expenses before long-term incentive compensation and the impact of market value adjustments related to deferred compensation trusts $259,376 $232,797
Impact of market value adjustments related to assets held in deferred compensation trusts 9,770 5,093
Long-term incentive compensation 5,508 5,523
Total SG&A expenses $274,654 $243,413

SG&A expenses before long-term incentive compensation and the impact of market value adjustments related to deferred compensation trusts for the first nine months of 2021 were up 11.4% when compared to the first nine months of 2020. This increase was mainly a result of the increase in variable selling and general administrative expenses and increased bonus expense at Roto-Rooter caused by increased income.

Depreciation for the first nine months of 2021 increased 6.9% when compared to the first nine months of 2020.

Amortization for the first nine months of 2021 increased 0.7% when compared to the first nine months of 2020. Quarterly amortization of intangible assets is mainly driven by two Roto-Rooter franchise acquisitions completed in 2019. The total purchase price of these acquisitions was $138.0 million. As part of the purchase price allocation, approximately $59.2 million was determined to be the value of reacquired franchise rights which are being amortized over the remaining life of each franchise agreement. The average remaining life on the reacquired franchise agreements was approximately seven years. Quarterly amortization of reacquired franchise rights for these two acquisitions is approximately $2.0 million ($8.1 million annualized through 2026). This contrasts to quarterly franchise fees historically collected from these two franchisees of approximately $470,000 ($1.9 million annualized).

Other operating (income)/expenses comprise the following:

Nine months ended September 30, 2021 2020
Loss on disposal of fixed assets $789 $154
CARES Act grant - (32,184)
Litigation settlement - 3,095
Total other operating (income)/expenses $789 $(28,935)

Other income – net comprise (in thousands):

Nine months ended September 30, 2021 2020
Market value adjustment on assets held in deferred compensation trusts $9,770 $5,093
Interest income 288 647
Other 463 (17)
Total other income - net $10,521 $5,723

Our effective tax rate reconciliation is as follows (in thousands):

Nine months ended September 30, 2021 2020
Income tax provision calculated at the statutory federal rate $53,379 $52,531
Stock compensation tax benefits (5,305) (19,943)
State and local income taxes 9,332 9,118
Other--net 2,856 2,729
Income tax provision $60,262 $44,435
Effective tax rate 23.7% 17.8%

Net income for both periods included the following after-tax items/adjustments that (reduced) or increased after-tax earnings (in thousands):

VITAS Nine months ended September 30, 2021 2020
Direct costs related to COVID-19 $(11,442) $(24,009)
Facility relocation costs (1,384) -
CARES Act grant - 24,009
Medicare cap sequestration adjustment - (462)
Roto-Rooter
Amortization of reacquired franchise agreements (5,186) (5,185)
Direct costs related to COVID-19 (1,140) (2,426)
Litigation settlements 72 (2,275)
Corporate
Stock option expense (13,695) (11,369)
Excess tax benefits on stock compensation 5,305 19,943
Long-term incentive compensation (4,964) (5,006)
Direct costs related to COVID-19 (29) -
Other (166) -
Total $(32,629) $(6,780)

Nine months ended September 30, 2021 versus 2020 - Segment Results

Net income/(loss) for the first nine months of 2021 versus the first nine months of 2020 by segment (in thousands):

Nine months ended September 30, 2021 2020
VITAS $113,430 $147,262
Roto-Rooter 124,504 84,966
Corporate (44,009) (26,514)
$193,925 $205,714

VITAS’ after-tax earnings decreased primarily due to lower revenue. After-tax earnings as a percent of revenue at VITAS in the first nine months of 2021 was 12.0% as compared to 14.7% in the first nine months of 2020.

Roto-Rooter’s net income was impacted in 2021 compared to 2020 primarily by higher revenue and improved labor costs. After-tax earnings as a percent of revenue at Roto-Rooter in the first nine months of 2021 was 19.1%, as compared to 15.6% in the first nine months of 2020.

After-tax Corporate expenses for 2021 increased 66.0% when compared to 2020 due mainly to a $14.6 million decrease in the excess tax benefits on stock compensation.

CHEMED CORPORATION AND SUBSIDIARY COMPANIES

CONSOLIDATING STATEMENTS OF INCOME

FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2021

(in thousands)(unaudited)

2021 (a) VITAS Roto-Rooter Corporate Chemed Consolidated
Service revenues and sales $317,411 $221,256 $- $538,667
Cost of services provided and goods sold 238,212 103,952 - 342,164
Selling, general and administrative expenses 21,372 51,914 15,931 89,217
Depreciation 5,286 6,539 19 11,844
Amortization 18 2,492 - 2,510
Other operating expense/(income) 65 (3) 1 63
Total costs and expenses 264,953 164,894 15,951 445,798
Income/(loss) from operations 52,458 56,362 (15,951) 92,869
Interest expense (43) (285) (255) (583)
Intercompany interest income/(expense) 4,513 1,847 (6,360) -
Other income—net 22 34 3,078 3,134
Income/(expense) before income taxes 56,950 57,958 (19,488) 95,420
Income taxes (14,000) (13,404) 3,987 (23,417)
Net income/(loss) $42,950 $44,554 $(15,501) $72,003
(a) The following amounts are included in net income (in thousands):
Chemed
VITAS Roto-Rooter Corporate Consolidated
Pretax benefit/(cost):
Stock option expense $- - (3,998) $(3,998)
Direct costs related to COVID-19 (2,501) $(415) $- (2,916)
Amortization of reacquired franchise agreements - (2,352) - (2,352)
Long-term incentive compensation - - (1,942) (1,942)
Other - - (218) (218)
Total $(2,501) $(2,767) $(6,158) $(11,426)
Chemed
VITAS Roto-Rooter Corporate Consolidated
After-tax benefit/(cost):
Stock option expense $- - (3,462) $(3,462)
Direct costs related to COVID-19 (1,866) $(305) $- (2,171)
Amortization of reacquired franchise agreements - (1,729) - (1,729)
Long-term incentive compensation - - (1,752) (1,752)
Other - - (166) (166)
Excess tax benefits on stock compensation - - 1,199 1,199
Total $(1,866) $(2,034) $(4,181) $(8,081)

CHEMED CORPORATION AND SUBSIDIARY COMPANIES

CONSOLIDATING STATEMENTS OF INCOME

FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2020

(in thousands)(unaudited)

2020 (a) VITAS Roto-Rooter Corporate Chemed Consolidated
Service revenues and sales $337,097 $191,200 $- $528,297
Cost of services provided and goods sold 246,636 92,604 - 339,240
Selling, general and administrative expenses 21,799 48,074 18,444 88,317
Depreciation 5,592 6,089 33 11,714
Amortization 18 2,493 - 2,511
Other operating expense 9,052 3,155 - 12,207
Total costs and expenses 283,097 152,415 18,477 453,989
Income/(loss) from operations 54,000 38,785 (18,477) 74,308
Interest expense (47) (80) (252) (379)
Intercompany interest income/(expense) 5,337 1,651 (6,988) -
Other income—net 381 38 7,256 7,675
Income/(expense) before income taxes 59,671 40,394 (18,461) 81,604
Income taxes (13,934) (9,218) 9,270 (13,882)
Net income/(loss) $45,737 $31,176 $(9,191) $67,722
(a) The following amounts are included in net income (in thousands):
Chemed
VITAS Roto-Rooter Corporate Consolidated
Pretax benefit/(cost):
CARES Act grant $(8,805) $- $- $(8,805)
Direct costs related to COVID-19 (6,945) (1,321) - (8,266)
Stock option expense - - (3,182) (3,182)
Litigation settlement (3,095) (3,095)
Amortization of reacquired franchise agreements - (2,352) - (2,352)
COVID-19 Medicare cap 2,250 - - 2,250
Long-term incentive compensation - - (1,774) (1,774)
Medicare cap sequestration adjustment 852 - - 852
Total $(12,648) $(6,768) $(4,956) $(24,372)
Chemed
VITAS Roto-Rooter Corporate Consolidated
After-tax benefit/(cost):
CARES Act grant $(6,528) $- $- $(6,528)
Direct costs related to COVID-19 (5,181) (971) - (6,152)
Stock option expense - - (2,970) (2,970)
Litigation settlement (2,275) (2,275)
Amortization of reacquired franchise agreements - (1,728) - (1,728)
Long-term incentive compensation - - (1,682) (1,682)
COVID-19 Medicare cap 1,679 - - 1,679
Medicare cap sequestration adjustment 635 - - 635
Excess tax benefits on stock compensation - - 7,187 7,187
Total $(9,395) $(4,974) $2,535 $(11,834)

CHEMED CORPORATION AND SUBSIDIARY COMPANIES

CONSOLIDATING STATEMENTS OF INCOME

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2021

(in thousands)(unaudited)

2021 (a) VITAS Roto-Rooter Corporate Chemed Consolidated
Service revenues and sales $945,135 $653,148 $- $1,598,283
Cost of services provided and goods sold 724,398 308,732 - 1,033,130
Selling, general and administrative expenses 66,094 158,791 49,769 274,654
Depreciation 17,749 19,359 63 37,171
Amortization 53 7,477 - 7,530
Other operating expense 655 133 1 789
Total costs and expenses 808,949 494,492 49,833 1,353,274
Income/(loss) from operations 136,186 158,656 (49,833) 245,009
Interest expense (129) (464) (750) (1,343)
Intercompany interest income/(expense) 13,524 5,116 (18,640) -
Other income—net 654 97 9,770 10,521
Income/(expense) before income taxes 150,235 163,405 (59,453) 254,187
Income taxes (36,805) (38,901) 15,444 (60,262)
Net income/(loss) $113,430 $124,504 $(44,009) $193,925
(a) The following amounts are included in net income (in thousands):
Chemed
VITAS Roto-Rooter Corporate Consolidated
Pretax benefit/(cost):
Direct costs related to COVID-19 $(15,338) $(1,551) $(38) $(16,927)
Stock option expense - - (16,342) (16,342)
Amortization of reacquired franchise agreements - (7,056) - (7,056)
Long-term incentive compensation - - (5,508) (5,508)
Facility relocation costs (1,855) - - (1,855)
Litigation settlement - 98 - 98
Other - - (218) (218)
Total $(17,193) $(8,509) $(22,106) $(47,808)
Chemed
VITAS Roto-Rooter Corporate Consolidated
After-tax benefit/(cost):
Stock option expense $- $- $(13,695) $(13,695)
Direct costs related to COVID-19 (11,442) (1,140) (29) (12,611)
Amortization of reacquired franchise agreements - (5,186) - (5,186)
Long-term incentive compensation - - (4,964) (4,964)
Facility relocation costs (1,384) - - (1,384)
Litigation settlement - 72 - 72
Other - - (166) (166)
Excess tax benefits on stock compensation - - 5,305 5,305
Total $(12,826) $(6,254) $(13,549) $(32,629)

CHEMED CORPORATION AND SUBSIDIARY COMPANIES

CONSOLIDATING STATEMENTS OF INCOME

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2020

(in thousands)(unaudited)

2020 (a) VITAS Roto-Rooter Corporate Chemed Consolidated
Service revenues and sales $1,002,477 $543,817 $- $1,546,294
Cost of services provided and goods sold 772,880 270,268 - 1,043,148
Selling, general and administrative expenses 65,141 138,587 39,685 243,413
Depreciation 16,622 18,035 104 34,761
Amortization 53 7,423 - 7,476
Other operating (income)/expense (31,661) 2,725 1 (28,935)
Total costs and expenses 823,035 437,038 39,790 1,299,863
Income/(loss) from operations 179,442 106,779 (39,790) 246,431
Interest expense (137) (272) (1,596) (2,005)
Intercompany interest income/(expense) 14,463 4,422 (18,885) -
Other income—net 549 68 5,106 5,723
Income/(expense) before income taxes 194,317 110,997 (55,165) 250,149
Income taxes (47,055) (26,031) 28,651 (44,435)
Net income/(loss) $147,262 $84,966 $(26,514) $205,714
(a) The following amounts are included in net income (in thousands):
Chemed
VITAS Roto-Rooter Corporate Consolidated
Pretax benefit/(cost):
Direct costs related to COVID-19 $(32,184) $(3,299) $- $(35,483)
CARES Act grant 32,184 - - 32,184
Stock option expense - - (13,296) (13,296)
Amortization of reacquired franchise agreements - (7,056) - (7,056)
Long-term incentive compensation - - (5,523) (5,523)
Litigation Settlement - (3,095) - (3,095)
Medicare cap sequestration adjustment (619) - - (619)
Total $(619) $(13,450) $(18,819) $(32,888)
Chemed
VITAS Roto-Rooter Corporate Consolidated
After-tax benefit/(cost):
Direct costs related to COVID-19 $(24,009) $(2,426) $- $(26,435)
CARES Act grant 24,009 - - 24,009
Stock option expense - - (11,369) (11,369)
Amortization of reacquired franchise agreements - (5,185) - (5,185)
Long-term incentive compensation - - (5,006) (5,006)
Litigation settlement - (2,275) - (2,275)
Medicare cap sequestration adjustment (462) - - (462)
Excess tax benefits on stock compensation - - 19,943 19,943
Total $(462) $(9,886) $3,568 $(6,780)

Unaudited Consolidating Summary and Reconciliation of Adjusted EBITDA

(in thousands)

Chemed Corporation and Subsidiary Companies For the three months ended Setptember 30, 2021 VITAS Roto-Rooter Corporate Chemed Consolidated
Net income/(loss) $42,950 $44,554 $(15,501) $72,003
Add/(deduct):
Interest expense 43 285 255 583
Income taxes 14,000 13,404 (3,987) 23,417
Depreciation 5,286 6,539 19 11,844
Amortization 18 2,492 - 2,510
EBITDA 62,297 67,274 (19,214) 110,357
Add/(deduct):
Intercompany interest expense/(income) (4,513) (1,847) 6,360 -
Interest income (24) (34) - (58)
Stock option expense - - 3,998 3,998
Direct costs related to COVID-19 2,501 415 - 2,916
Long-term incentive compensation - - 1,942 1,942
Other - - 218 218
Adjusted EBITDA $60,261 $65,808 $(6,696) $119,373
Chemed
For the three months ended September 30, 2020 VITAS Roto-Rooter Corporate Consolidated
Net income/(loss) $45,737 $31,176 $(9,191) $67,722
Add/(deduct):
Interest expense 47 80 252 379
Income taxes 13,934 9,218 (9,270) 13,882
Depreciation 5,592 6,089 33 11,714
Amortization 18 2,493 - 2,511
EBITDA 65,328 49,056 (18,176) 96,208
Add/(deduct):
Intercompany interest expense/(income) (5,337) (1,651) 6,988 -
Interest (income)/expense (385) (38) - (423)
CARES Act grant 8,805 - - 8,805
Direct costs related to COVID-19 6,945 1,321 - 8,266
Stock option expense - - 3,182 3,182
Litigation Settlement - 3,095 - 3,095
COVID-19 related Medicare cap (2,250) - - (2,250)
Long-term incentive compensation - - 1,774 1,774
Medicare cap sequestration adjustment (852) - - (852)
Adjusted EBITDA $72,254 $51,783 $(6,232) $117,805

Unaudited Consolidating Summary and Reconciliation of Adjusted EBITDA

(in thousands)

Chemed Corporation and Subsidiary Companies For the nine months ended September 30, 2021 VITAS Roto-Rooter Corporate Chemed Consolidated
Net income/(loss) $113,430 $124,504 $(44,009) $193,925
Add/(deduct):
Interest expense 129 464 750 1,343
Income taxes 36,805 38,901 (15,444) 60,262
Depreciation 17,749 19,359 63 37,171
Amortization 53 7,477 - 7,530
EBITDA 168,166 190,705 (58,640) 300,231
Add/(deduct):
Intercompany interest expense/(income) (13,524) (5,116) 18,640 -
Interest income (191) (97) - (288)
Direct costs related to COVID-19 15,338 1,551 38 16,927
Stock option expense - - 16,342 16,342
Long-term incentive compensation - - 5,508 5,508
Litigation settlement - (98) - (98)
Other - - 218 218
Adjusted EBITDA $169,789 $186,945 $(17,894) $338,840
Chemed
For the nine months ended September 30, 2020 VITAS Roto-Rooter Corporate Consolidated
Net income/(loss) $147,262 $84,966 $(26,514) $205,714
Add/(deduct):
Interest expense 137 272 1,596 2,005
Income taxes 47,055 26,031 (28,651) 44,435
Depreciation 16,622 18,035 104 34,761
Amortization 53 7,423 - 7,476
EBITDA 211,129 136,727 (53,465) 294,391
Add/(deduct):
Intercompany interest expense/(income) (14,463) (4,422) 18,885 -
Interest income (566) (68) (13) (647)
Direct costs related to COVID-19 32,184 3,299 - 35,483
CARES Act grant (32,184) - - (32,184)
Stock option expense - - 13,296 13,296
Long-term incentive compensation - - 5,523 5,523
Litigation settlement - 3,095 - 3,095
Medicare cap sequestration adjustment 619 - - 619
Adjusted EBITDA $196,719 $138,631 $(15,774) $319,576

RECONCILIATION OF ADJUSTED NET INCOME

(in thousands, except per share data)(unaudited)

Three Months Ended September 30, 2021 2020 Nine Months Ended September 30, 2021 2020
Net income as reported $72,003 $67,722 $193,925 $205,714
Add/(deduct) pre-tax cost of:
Direct costs related to COVID-19 2,916 8,266 16,927 35,483
Stock option expense 3,998 3,182 16,342 13,296
Amortization of reacquired franchise agreements 2,352 2,352 7,056 7,056
Long-term incentive compensation 1,942 1,774 5,508 5,523
Facility relocation costs - - 1,855 -
Litigation settlements - 3,095 (98) 3,095
Other 218 - 218
COVID-19 related Medicare cap - (2,250) - -
CARES Act grant - 8,805 - (32,184)
Medicare cap sequestration adjustment - (852) - 619
Add/(deduct) tax impacts:
Tax impact of the above pre-tax adjustments (1) (2,146) (5,351) (9,874) (6,165)
Excess tax benefits on stock compensation (1,199) (7,187) (5,305) (19,943)
Adjusted net income $80,084 $79,556 $226,554 $212,494
Diluted Earnings Per Share As Reported
Net income $4.55 $4.14 $12.06 $12.53
Average number of shares outstanding 15,842 16,373 16,083 16,419
Adjusted Diluted Earnings Per Share
Adjusted net income $5.06 $4.86 $14.09 $12.94
Adjusted average number of shares outstanding 15,842 16,373 16,083 16,419
(1) The tax impact of pre-tax adjustments was calculated using the effective tax rate of the operating unit for which each adjustment is associated.

CHEMED CORPORATION AND SUBSIDIARY COMPANIES

OPERATING STATISTICS FOR VITAS SEGMENT

(unaudited)

OPERATING STATISTICS Net revenue ($000) Three Months Ended September 30, 2021 2020 Nine Months Ended September 30, 2021 2020
Homecare $268,137 $278,856 $796,817 $826,954
Inpatient 29,368 27,633 85,895 85,983
Continuous care 22,027 30,699 73,658 105,836
Other 3,225 2,910 9,241 8,175
Subtotal $322,757 $340,098 $965,611 $1,026,948
Room and board, net (2,130) (3,289) (7,451) (9,317)
Contractual allowances (3,119) (3,784) (9,428) (10,976)
Medicare cap allowance (97) 4,072 (3,597) (4,178)
Total $317,411 $337,097 $945,135 $1,002,477
Net revenue as a percent of total before Medicare cap allowances
Homecare 83.1% 82.0% 82.5% 80.5%
Inpatient 9.1 8.1 8.9 8.4
Continuous care 6.8 9.0 7.6 10.3
Other 1.0 0.9 1.0 0.8
Subtotal 100.0 100.0 100.0 100.0
Room and board, net (0.7) (1.0) (0.8) (0.9)
Contractual allowances (1.0) (1.1) (1.0) (1.1)
Medicare cap allowance - 1.2 (0.3) (0.4)
Total 98.3% 99.1% 97.9% 97.6%
Days of care
Homecare 1,342,841 1,426,191 4,008,215 4,192,681
Nursing home 258,700 261,396 735,906 844,232
Respite 5,331 4,566 15,509 15,416
Subtotal routine homecare and respite 1,606,872 1,692,153 4,759,630 5,052,329
Inpatient 27,962 27,017 82,129 84,907
Continuous care 24,299 33,013 79,385 110,200
Total 1,659,133 1,752,183 4,921,144 5,247,436
Number of days in relevant time period 92 92 273 274
Average daily census (days)
Homecare 14,596 15,502 14,682 15,302
Nursing home 2,812 2,841 2,696 3,081
Respite 58 50 57 56
Subtotal routine homecare and respite 17,466 18,393 17,435 18,439
Inpatient 304 294 301 310
Continuous care 264 358 291 402
Total 18,034 19,045 18,027 19,151
Total Admissions 17,598 17,943 52,573 53,368
Total Discharges 17,686 18,205 52,747 51,281
Average length of stay (days) 96.0 97.1 95.0 92.9
Median length of stay (days) 13.0 14.0 13.0 14.0
ADC by major diagnosis
Cerebro 36.4% 35.1% 36.7% 35.7%
Neurological 22.7 22.1 22.5 21.7
Cancer 12.0 12.5 12.1 12.6
Cardio 15.5 16.1 15.5 15.9
Respiratory 7.5 8.0 7.5 8.2
Other 5.9 6.2 5.7 5.9
Total 100.0% 100.0% 100.0% 100.0%
Admissions by major diagnosis
Cerebro 20.3 21.4% 21.1% 21.2%
Neurological 12.1 13.2 12.2 13.0
Cancer 27.0 27.4 26.9 27.8
Cardio 14.1 13.6 14.4 14.5
Respiratory 11.3 9.9 10.9 10.6
Other 15.2 14.5 14.5 12.9
Total 100.0% 100.0% 100.0% 100.0%
Estimated uncollectible accounts as a percent of revenues 1.0% 1.1% 1.0% 1.1%
Accounts receivable --
Days of revenue outstanding- excluding unapplied Medicare payments 33.7 33.4 n.a. n.a.
Days of revenue outstanding- including unapplied Medicare payments 23.4 22.1 n.a. n.a.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 Regarding Forward-Looking Information

Certain statements contained in this report are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The words “believe”, “expect”, “hope”, “anticipate”, “plan” and similar expressions identify forward-looking statements, which speak only as of the date the statement was made. These forward-looking statements are based on current expectations and assumptions and involve various known and unknown risks, uncertainties, contingencies and other factors, which could cause Chemed’s actual results to differ from those expressed in such forward-looking statements. Variances in any or all of the risks, uncertainties, contingencies, and other factors from our assumptions could cause actual results to differ materially from these forward-looking statements and trends. In addition, our ability to deal with the unknown outcomes of these events, many of which are beyond our control, may affect the reliability of projections and other financial matters. Investors are cautioned that such forward-looking statements are subject to inherent risk and there are no assurances that the matters contained in such statements will be achieved. Chemed does not undertake and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of a new information, future events or otherwise.

Market risk

As filed, 576 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The Company’s primary market risk exposure relates to interest rate risk exposure through its variable interest line of credit. At September 30, 2021, the Company had no variable rate debt outstanding. For each $10 million borrowed under the credit facility, an increase or decrease of 100 basis points (1%), increases or decreases the Company’s annual interest expense by $100,000.

The Company continually evaluates this interest rate exposure and periodically weighs the cost versus the benefit of fixing the variable interest rates through a variety of hedging techniques.

Controls and procedures

As filed, 900 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

We carried out an evaluation, under the supervision of our President and Chief Executive Officer and with the participation of the Executive Vice President and Chief Financial Officer and the Vice President and Controller, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, the President and Chief Executive Officer, Executive Vice President and Chief Financial Officer and Vice President and Controller have concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report. There has been no change in our internal control over financial reporting that occurred during the quarter covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Risk factors

As filed, 141 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

There have been no other material changes from the risk factors previously disclosed in the Company’s most recent Annual Report on Form 10-K.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2021-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Cost of revenue3 months2021-07-01 to 2021-09-30$342.2mus-gaap:CostOfGoodsAndServicesSold
Cost of revenue9 months2021-01-01 to 2021-09-30$1.03bnus-gaap:CostOfGoodsAndServicesSold
Selling, general and administrative3 months2021-07-01 to 2021-09-30$89.2mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative9 months2021-01-01 to 2021-09-30$274.7mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2021-07-01 to 2021-09-30$92.9mus-gaap:OperatingIncomeLoss
Operating income9 months2021-01-01 to 2021-09-30$245.0mus-gaap:OperatingIncomeLoss
Interest expense3 months2021-07-01 to 2021-09-30$583.0kus-gaap:InterestExpense
Interest expense9 months2021-01-01 to 2021-09-30$1.3mus-gaap:InterestExpense
Income tax3 months2021-07-01 to 2021-09-30$23.4mus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2021-01-01 to 2021-09-30$60.3mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2021-07-01 to 2021-09-30$72.0mus-gaap:NetIncomeLoss
Net income9 months2021-01-01 to 2021-09-30$193.9mus-gaap:NetIncomeLoss
Diluted EPS3 months2021-07-01 to 2021-09-30$4.55us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2021-01-01 to 2021-09-30$12.06us-gaap:EarningsPerShareDiluted
Basic EPS3 months2021-07-01 to 2021-09-30$4.62us-gaap:EarningsPerShareBasic
Basic EPS9 months2021-01-01 to 2021-09-30$12.27us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2021-07-01 to 2021-09-3015,842,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2021-01-01 to 2021-09-3016,083,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2021-01-01 to 2021-09-30$245.0mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2021-01-01 to 2021-09-30$44.5mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Dividends paid9 months2021-01-01 to 2021-09-30$16.5mus-gaap:PaymentsOfDividendsCommonStock
Share repurchases9 months2021-01-01 to 2021-09-30$330.4mus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2021-09-30$28.7mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2021-09-30$200.6mus-gaap:AssetsCurrent
Total assetsAt period end2021-09-30$1.32bnus-gaap:Assets
Current liabilitiesAt period end2021-09-30$286.1mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2021-09-30$538.4mus-gaap:Liabilities
Shareholders' equityAt period end2021-09-30$779.7mus-gaap:StockholdersEquity
Shares outstandingAt period end2021-09-3015,395,049 sharesdei:EntityCommonStockSharesOutstanding

Source: SEC EDGAR, the filing index for accession 0001562762-21-000385. Last ingested by Listed: Nov 14, 2026, 12:29 ET. Listed shows no prices and gives no investment advice.